Powder: -20°C for 3 years | In solvent: -80°C for 1 year
OGT 2115是一种肝素酶(IC50 = 0.4µM)抑制剂,肝素酶是一种将硫酸肝素分解成葡萄糖醛酸(GlcUA)和 n -乙酰氨基葡萄糖(GlcNAc)的酶。同时,OGT 2115也具有抗血管生成性能(IC50=1 μM)。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 283 | 现货 | ||
5 mg | ¥ 652 | 现货 | ||
10 mg | ¥ 1,160 | 现货 | ||
25 mg | ¥ 2,490 | 现货 | ||
50 mg | ¥ 3,770 | 现货 | ||
100 mg | ¥ 5,420 | 现货 | ||
500 mg | ¥ 11,300 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 721 | 现货 |
产品描述 | OGT 2115 is an inhibitor of heparanase (IC50 = 0.4 µM), an enzyme that cleaves heparan sulfate into glucuronic acid (GlcUA) and N-acetylglucosamine (GlcNAc). OGT 2115 also showed antiangiogenic properties (IC50=1 μM). |
靶点活性 | Heparanase:0.4 μM |
体外活性 | OGT 2115 obviously inhibits the invasion and migration induced by Adriamycin. Furthermore, the MTT assay results display that OGT 2115 does not decrease the anti-proliferative effect of Adriamycin. Heparanase InhibitorOGT 2115 can inhibit metastasis induced by endoplasmic reticulum (ER) stress in breast cancer cells, although not significantly. The number and rate of migrated cells are significantly reduced following the exposure of the cells to Tunicamycin + OGT 2115, compared with the control group [2]. |
体内活性 | OGT 2115 displays a plasma concentration of ~10x the heparanase IC50 following oral dosing at 20 mg/kg when administered to mice[1]. |
分子量 | 495.3 |
分子式 | C24H16BrFN2O4 |
CAS No. | 853929-59-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 10.2 mg/mL (20.6 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.019 mL | 10.0949 mL | 20.1898 mL | 50.4745 mL |
5 mM | 0.4038 mL | 2.019 mL | 4.038 mL | 10.0949 mL | |
10 mM | 0.2019 mL | 1.0095 mL | 2.019 mL | 5.0474 mL | |
20 mM | 0.1009 mL | 0.5047 mL | 1.0095 mL | 2.5237 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
OGT 2115 853929-59-6 Others OGT2115 OGT-2115 Inhibitor inhibitor inhibit